The NCT06530719 study is an active study that is not yet recruiting aiming to verify the efficacy and safety of osimertinib rechallenge in patients with EGFR-mutant NSCLC, who progressed after adjuvant targeted therapy following radical surgery. Here, EGFR is linked to non-small cell lung carcinoma.